Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Wang DG, et al. Among authors: bromberg jf. Breast Cancer Res Treat. 2020 Aug;183(1):227-237. doi: 10.1007/s10549-020-05726-y. Epub 2020 Jun 29. Breast Cancer Res Treat. 2020. PMID: 32613539 Free PMC article.
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2007 Jan 1;13(1):223-7. doi: 10.1158/1078-0432.CCR-06-1731. Clin Cancer Res. 2007. PMID: 17200358 Clinical Trial.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. Dickler MN, et al. Among authors: bromberg jf. Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141. Clin Cancer Res. 2008. PMID: 19047117 Free PMC article. Clinical Trial.
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. Fornier MN, et al. Ann Oncol. 2011 Dec;22(12):2575-2581. doi: 10.1093/annonc/mdr018. Epub 2011 Mar 15. Ann Oncol. 2011. PMID: 21406471 Free PMC article. Clinical Trial.
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN. Morris PG, et al. Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15. Clin Breast Cancer. 2018. PMID: 29680193 Free PMC article. Clinical Trial.
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Ross DS, et al. Among authors: bromberg jf. Ann Oncol. 2020 Aug;31(8):991-1000. doi: 10.1016/j.annonc.2020.04.008. Epub 2020 Apr 26. Ann Oncol. 2020. PMID: 32348852 Free PMC article.
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schöder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, Larson SM. Dunphy MPS, et al. Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4. Clin Cancer Res. 2020. PMID: 32366671 Free PMC article. Clinical Trial.
Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Jhaveri KL, et al. Among authors: bromberg jf. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283132 Free PMC article.
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, Quigley EA, Haliasos HC, Moy AP, Schram AM, Bromberg J, Funt SA, Voss MH, Drilon A, Hellmann MD, Comen EA, Narala S, Patel AB, Wetzel M, Jung JY, Leung DYM, Lacouture ME. Barrios DM, et al. Ann Oncol. 2021 Jun;32(6):736-745. doi: 10.1016/j.annonc.2021.02.016. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33667669 Free PMC article.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Walsh EM, et al. Breast Cancer Res Treat. 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20. Breast Cancer Res Treat. 2022. PMID: 35986801 Free PMC article.
93 results